Georg Lenz from the University of Münster, Münster, Germany discusses the current unmet need in diffuse large B-cell lymphoma (DLBCL), which he states to be patients who do not respond to the current standard treatment of rituximab plus CHOP chemotherapy. Recorded at the European Hematology Association (EHA) 2016 Annual Congress in Copenhagen, Denmark.
The unmet need in DLBCL
